Re: Lack of Evidence of Ginkgo and Antiplatelet or Anticoagulant Drug Interactions
Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res. 2008;52(7): 764-771.
Ginkgo (Ginkgo biloba) has become one
of the best-selling herbs on the global market. Ginkgo products come in various
formulations and compositions, including EGb 761® (Dr. Willmar Schwabe;
Karlsruhe, Germany) which is a highly concentrated extract of ginkgo leaves,
standardized by total flavonoid and terpene trilactone content. However,
generic standardized ginkgo products do not reflect the same phytochemical
profile as EGb 761.
Regular ginkgo intake has been linked with bleeding
episodes, and the potential interaction of ginkgo with antiplatelet or
anticoagulant drugs has become an accepted notion.This review sought to critically examine the
likelihood that ginkgo (and specifically EGb 761 or extracts which mimic its
phytochemical profile) influences normal hemostasis.
The author notes that there is no evidence from
controlled studies that normal doses of EGb 761 (or closely similar extracts)
have any impact on hemostasis. Furthermore, earlier ex vivo platelet
aggregation studies using high doses or a concentrated ginkgolide mixture have
been inappropriately extrapolated to the normal use of commercial extracts.
Although in vitro studies have shown that single constituents of EGb 761
(especially ginkgolide B) inhibit platelet aggregation, the results should be interpreted
with caution because there are issues of oral bioavailability and excessive
concentrations. One study revealed that aggregation of human platelets was
inhibited by ginkgolides at concentrations generally more than 100 times higher
than the peak plasma values measured after oral intake of EGb 761.
In perhaps the most comprehensive study to
date, the effect of 240 mg/day for 7 days of EGb 761 in 50 healthy male
volunteers was assessed using a randomized, double-blind, placebo-controlled
crossover design. None of the 29 coagulation and bleeding parameters evaluated
showed any evidence of an inhibition of blood coagulation or platelet
aggregation from EGb 761 intake. Four small, controlled studies found no
additional impact on hemostasis when EGb 761 was combined with either aspirin
or warfarin.
The results from controlled studies appear to
be at odds with the 21 case reports published between 1996 and 2005, which
describe adverse bleeding events in connection with the consumption of ginkgo. Although
there was a single documented case report in which it was confirmed that EGb
761 was involved in the bleeding, the patient was also taking aspirin. Establishing
causality from these case reports is difficult, due to the generally low
quality of the reports. Not only is there variability in herbal products, but
also a lack of documentation of key factors such as product name, level of
standardization, other potentially active ingredients, and type of extract used
are generally absent. Further confounding any interpretation, in most of the
reported cases, other clinical risk factors for bleeding were present. Nevertheless,
these case reports do serve as a warning for a potential problem. The author
suggests that there is scant evidence, based on either the case reports or
controlled studies, to suggest that combining ginkgo with anticoagulant or antiplatelet
agents increases the risk of bleeding over and above the use of these agents
alone.
Reviews and meta-analyses of clinical trials
have shown that EGb 761 has a remarkably low incidence of side effects. In 44
clinical trials, only 0.5% of 9772 patients reported adverse events, and none
of the events were linked to abnormal bleeding. An excerpt of the Mediplus
database in Germany providing information for 320,644 patients was used to
evaluate reported bleeding events. Over 810,077 patient years of observation, 22,586
bleeding events were reported, giving an average of 2.79 events per 100 years
of observation. The risk of bleeding with EGb 761 or any ginkgo preparation was
around 1, indicating that the frequency of reported bleeding events in patients
taking ginkgo was the same as that in patients not taking ginkgo. No increase
in the prevalence of bleeding during EGb 761 intake compared to periods without
EGb 761 was seen for coadministration of phenprocoumon, aspirin, or for any
other anticoagulant or antiplatelet medication.
The author concludes that results from
controlled clinical trials together with those from the surveillance (database)
study suggest that concerns regarding the potential for ginkgo to interact
adversely with anticoagulant and antiplatelet drugs are substantially
overstated, especially if EGb 761 or phytochemically similar extracts are
involved. However, the amounts and relative levels of the various ginkgolides, the
fortification with added flavonoids, or the lack of removal of ginkgolic acids might
account for a less favorable safety profile for other ginkgo extracts in terms
of bleeding risk. On the other hand, the reported cases may represent an
idiosyncratic reaction to ginkgo, but better data are required to establish
this.
The American Botanical Council provides this review
as an educational service.By
providing this service, ABC does not warrant that the data is accurate and
correct, nor does distribution of the article constitute any endorsement of
the information contained or of the views of the authors.
ABC does not authorize the copying or use of the
original articles.Reproduction of
the reviews is allowed on a limited basis for students, colleagues,
employees and/or members.Other uses
and distribution require prior approval from ABC.